Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestane in first and subsequent lines. Best overall response (BR) and clinical benefit rate (CBR) were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI). Survival was estimated by Kaplan-Meier method and log-rank test. Survival predictors were tested in Cox models. Median follow up was 12.4 months (1.0-41.0). The overall cohort showed increasing levels of FG and decreasing BMI (p < 0.001). Lower FG fasting glucose at BR was more commonly associated with C/PR or SD compared with PD (p < 0.001). We also observed a somewhat higher BMI associated with better response (p = 0.052). More patients in the lowest FG category achieved clinical benefit compared to the highest (p < 0.001), while no relevant differences emerged for BMI. Fasting glucose at re-assessment was also predictive of PFS (p = 0.037), as confirmed in models including BMI and line of therapy (p = 0.049). Treatment discontinuation was significantly associated with changes in FG (p = 0.014). Further research is warranted to corroborate these findings and clarify the underlying mechanisms.

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study / Pizzuti, Laura; Marchetti, Paolo; Natoli, Clara; Gamucci, Teresa; Santini, Daniele; Scinto, Angelo Fedele; Iezzi, Laura; Mentuccia, Lucia; D'Onofrio, Loretta; Botticelli, Andrea; Moscetti, Luca; Sperati, Francesca; Botti, Claudio; Ferranti, Francesca; Buglioni, Simonetta; Sanguineti, Giuseppe; Di Filippo, Simona; Di Lauro, Luigi; Sergi, Domenico; Catenaro, Teresa; Tomao, Silverio; Giordano, Antonio; Maugeri-saccà, Marcello; Barba, Maddalena; Vici, Patrizia. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 7:1(2017). [10.1038/s41598-017-10061-2]

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study

Pizzuti, Laura
Primo
;
Marchetti, Paolo
Secondo
;
Santini, Daniele;Mentuccia, Lucia;Botticelli, Andrea;Di Filippo, Simona;Tomao, Silverio;Barba, Maddalena
Penultimo
;
2017

Abstract

Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestane in first and subsequent lines. Best overall response (BR) and clinical benefit rate (CBR) were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI). Survival was estimated by Kaplan-Meier method and log-rank test. Survival predictors were tested in Cox models. Median follow up was 12.4 months (1.0-41.0). The overall cohort showed increasing levels of FG and decreasing BMI (p < 0.001). Lower FG fasting glucose at BR was more commonly associated with C/PR or SD compared with PD (p < 0.001). We also observed a somewhat higher BMI associated with better response (p = 0.052). More patients in the lowest FG category achieved clinical benefit compared to the highest (p < 0.001), while no relevant differences emerged for BMI. Fasting glucose at re-assessment was also predictive of PFS (p = 0.037), as confirmed in models including BMI and line of therapy (p = 0.049). Treatment discontinuation was significantly associated with changes in FG (p = 0.014). Further research is warranted to corroborate these findings and clarify the underlying mechanisms.
fasting glucose; body mass index; breast cancer; everolimus-exemestane; hyperglycemia
01 Pubblicazione su rivista::01a Articolo in rivista
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study / Pizzuti, Laura; Marchetti, Paolo; Natoli, Clara; Gamucci, Teresa; Santini, Daniele; Scinto, Angelo Fedele; Iezzi, Laura; Mentuccia, Lucia; D'Onofrio, Loretta; Botticelli, Andrea; Moscetti, Luca; Sperati, Francesca; Botti, Claudio; Ferranti, Francesca; Buglioni, Simonetta; Sanguineti, Giuseppe; Di Filippo, Simona; Di Lauro, Luigi; Sergi, Domenico; Catenaro, Teresa; Tomao, Silverio; Giordano, Antonio; Maugeri-saccà, Marcello; Barba, Maddalena; Vici, Patrizia. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 7:1(2017). [10.1038/s41598-017-10061-2]
File allegati a questo prodotto
File Dimensione Formato  
Pizzuti_Fasting-glucose_2017.pdf

accesso aperto

Note: https://www.nature.com/articles/s41598-017-10061-2
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.21 MB
Formato Adobe PDF
1.21 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1022499
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact